{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:17:10Z","timestamp":1790615830035,"version":"4.1.0"},"reference-count":21,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Central retinal artery occlusion (CRAO) is a vision-threatening vascular emergency that often causes permanent monocular visual loss. We report a woman in her late seventies with metastatic hormone receptor-positive, HER2-negative breast cancer and multiple myeloma who developed sudden, painless right monocular vision loss while receiving long-term abemaciclib and lenalidomide. Funduscopic examination showed diffuse retinal whitening, attenuated retinal arterioles and a cherry-red spot, confirming CRAO. She presented approximately 20 hours after symptom onset, outside the window for hyperacute intervention and severe visual impairment persisted. Evaluation showed severe hypertension and extensive cardiovascular comorbidity but no high-grade carotid stenosis, large-vessel occlusion or definite cardiac embolic source. Abemaciclib and lenalidomide have each been associated predominantly with venous thromboembolism. Given the patient\u2019s multiple vascular and malignancy-related risk factors, a treatment-related contribution, including a possible synergistic interaction, cannot be excluded.<\/jats:p>","DOI":"10.1136\/bcr-2025-271351","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:30:44Z","timestamp":1790613044000},"page":"e271351","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Abemaciclib and lenalidomide presenting with central retinal artery occlusion in a patient with breast cancer and multiple myeloma: a possible treatment-related association"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3566-0389","authenticated-orcid":false,"given":"Manas","family":"Pustake","sequence":"first","affiliation":[{"name":"Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevenson","family":"Ongsyping","sequence":"additional","affiliation":[{"name":"Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Gomez","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, University Medical Center of El Paso, El Paso, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Corral","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Texas Tech University Health Sciences El Paso, El Paso, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2026092809300717000_19.9.e271351.1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/eye.2013.25","article-title":"A review of central retinal artery occlusion: clinical presentation and management","volume":"27","author":"Varma","year":"2013","journal-title":"Eye (Lond)"},{"key":"2026092809300717000_19.9.e271351.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-018-0768-4","article-title":"Central retinal artery occlusion - rethinking retinal survival time","volume":"18","author":"Tobalem","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"2026092809300717000_19.9.e271351.3","unstructured":"Tripathy K , Shah SS , Waymack JR . Central retinal artery occlusion. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2024."},{"key":"2026092809300717000_19.9.e271351.4","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.694711","article-title":"Updates on Anticancer Therapy-Mediated Vascular Toxicity and New Horizons in Therapeutic Strategies","volume":"8","author":"Hsu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026092809300717000_19.9.e271351.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"2026092809300717000_19.9.e271351.6","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/ejh.13590","article-title":"CDK 4\/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice","volume":"106","author":"West","year":"2021","journal-title":"Eur J Haematol"},{"key":"2026092809300717000_19.9.e271351.7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081758","article-title":"Thromboembolic Events with Cyclin-Dependent Kinase 4\/6 Inhibitors in the FDA Adverse Event Reporting System","volume":"13","author":"Raschi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026092809300717000_19.9.e271351.8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23336"},{"key":"2026092809300717000_19.9.e271351.9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280893"},{"key":"2026092809300717000_19.9.e271351.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"2026092809300717000_19.9.e271351.11","doi-asserted-by":"crossref","first-page":"1558128","DOI":"10.3389\/fphar.2025.1558128","article-title":"Emerging cardiovascular toxicity associated with CDK4\/6 inhibitors: real-world insights from the FDA adverse event reporting system","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026092809300717000_19.9.e271351.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-025-04043-6","article-title":"CDK4\/6 inhibitor-associated vortex keratopathy: a case report","volume":"25","author":"Shu","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"2026092809300717000_19.9.e271351.13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.14740\/wjon1384","article-title":"Pulmonary Vein Thrombosis in a Patient With Multiple Myeloma on Treatment With Lenalidomide","volume":"12","author":"Stawiarski","year":"2021","journal-title":"World J Oncol"},{"key":"2026092809300717000_19.9.e271351.14","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-025-05415-8","article-title":"Combined retinal vein occlusion and retinal artery occlusion in a patient undergoing therapy for metastatic breast cancer: a case report","volume":"19","author":"Malvasi","year":"2025","journal-title":"J Med Case Rep"},{"key":"2026092809300717000_19.9.e271351.15","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13531"},{"key":"2026092809300717000_19.9.e271351.16","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2026092809300717000_19.9.e271351.17","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/bloodadvances.2021006484","article-title":"Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy","volume":"6","author":"Overvad","year":"2022","journal-title":"Blood Adv"},{"key":"2026092809300717000_19.9.e271351.18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209114"},{"key":"2026092809300717000_19.9.e271351.19","doi-asserted-by":"crossref","first-page":"100075","DOI":"10.1016\/j.tru.2021.100075","article-title":"Risk assessment models of cancer-associated thrombosis - Potentials and perspectives","volume":"5","author":"Moik","year":"2021","journal-title":"Thrombosis Update"},{"key":"2026092809300717000_19.9.e271351.20","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"2026092809300717000_19.9.e271351.21","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000366"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-271351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:30:49Z","timestamp":1790613049000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-271351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,28]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bcr-2025-271351"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-271351","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}